Abstract
Numerous model-based designs for dose-finding have been proposed to improve the phase I trials (e.g., increasing the accuracy to identify the maximum tolerated dose). However, algorithm-based designs (e.g., the 3＋3 design) are still dominantly used regardless of relatively poor performance due to the complexity of the implementation of the model-based designs. In this review, we introduce the model-assisted designs that have the simplicity of algorithm-based design and the similar performance to model-based designs, which are promising approaches to transcend the conventional framework. In addition, we comprehensively review the expansion of model-assisted designs to a complex area such as developments in dual-agent therapies; considerations of fast accrual issues or late-onset toxicities which would be observed in targeted therapies and immunotherapies; the exploration of optimal dose for efficacy and safety; and the other considerations (e.g., toxicity grades or historical data).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
